[CAR-T cells immunotherapy in multiple myeloma: Present and future]

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Multiple myeloma remains incurable, with limited options for refractory patients.
• Chimeric antigen receptor (CAR)-T cell therapy is a novel adoptive cell therapy approach.
• CAR-T strategies targeting B-cell maturation antigen (BCMA) are being explored for multiple myeloma.

Purpose of the Study:

• To review the current status and future directions of CAR-T cell therapy in multiple myeloma.
• To discuss challenges such as relapse and resistance in BCMA-targeted CAR-T therapy.
• To explore novel targets and strategies for enhancing CAR-T cell efficacy in multiple myeloma.

Main Methods:

• Review of existing literature on CAR-T cell therapy for multiple myeloma.
• Analysis of clinical trial data for BCMA-targeted CAR-T therapies like idecabtagene vicleucel.
• Discussion of strategies to improve CAR-T cell persistence and overcome antigen escape.

Main Results:

• Idecabtagene vicleucel (ide-cel) demonstrates significant efficacy in heavily pretreated multiple myeloma patients.
• Relapses remain a challenge, necessitating strategies to improve long-term outcomes.
• BCMA expression variability and tumor escape mechanisms are key areas for further research.

Conclusions:

• CAR-T cell therapy, particularly targeting BCMA, offers a promising therapeutic avenue for multiple myeloma.
• Further research is needed to enhance CAR-T cell persistence, overcome resistance, and identify new targets.
• The development of CAR-T therapies holds potential for prolonged remissions and possibly a cure for multiple myeloma.